Investors comparing ALEC and EDIT are weighing two distinct bets within biotechnology. Alector, Inc. develops immuno-neurology therapies for neurodegenerative diseases, while Editas Medicine, Inc. is a pioneer in CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing. Both are pre-revenue, cash-burning companies whose stock prices are driven largely by clinical data and financing decisions rather than earnings. This stock comparison is most relevant to biotech-focused traders and risk-tolerant investors assessing relative performance, market positioning, and the timing of potential catalysts in the current environment.
Alector, Inc. is a clinical-stage biopharmaceutical company advancing therapies that aim to counter neurodegeneration by engaging the immune system. Its share price has been under pressure in recent months after its lead program, latozinemab, failed to meet its primary endpoint in the Phase 3 INFRONT-3 trial in frontotemporal dementia. The company subsequently terminated that program and implemented a substantial workforce reduction of roughly 49%, refocusing resources on an earlier-stage pipeline and novel "BBB-shuttle" (blood-brain barrier) delivery approaches.
In recent weeks, analyst sentiment on ALEC has remained mixed. Several firms have maintained Hold or Sell ratings with sharply reduced price targets, while a few have turned more constructive on the pipeline reset. The stock trades near the low end of its 52-week range, and insider selling activity has added to a cautious tone. Alector's near-term story centers on cost discipline and early-pipeline optionality rather than an imminent clinical catalyst, which has kept relative performance subdued.
Editas Medicine, Inc. is a genome-editing company that has pivoted to an in vivo (within the living organism) CRISPR strategy. After discontinuing its reni-cel program in late 2024 and cutting its workforce, the company refocused on EDIT-401, an experimental one-time gene-editing therapy designed to reduce LDL ("bad") cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH). In recent weeks, Editas received approval to initiate the Phase 1/2 STRIVE clinical trial in Australia, a milestone that marked its return to the clinic.
That clearance prompted at least one major firm to upgrade EDIT, citing a potential value inflection as clinical proof-of-concept data arrives in 2027. The company reported roughly $211.6 million in cash and investments as of mid-2026 and has guided that its runway extends into the second half of 2028. Preclinical results showing approximately 90% or greater reductions in LDL cholesterol and related lipoproteins have underpinned renewed investor interest, supporting stronger relative momentum than Alector over the same period.
For traders seeking a systematic, data-driven perspective on names like ALEC and EDIT, Tickeron's Trending AI Robots page offers a curated view of the platform's most relevant automated strategies. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and statistics. Rather than listing every bot, Tickeron highlights only those best suited to prevailing market conditions. Because each bot operates with a distinct approach, reviewing the curated selection can help traders understand how algorithmic systems are currently positioned across volatile, catalyst-driven biotech names. Explore the Trending AI Robots to see which strategies are adapting to today's market.
Although both companies are speculative biotech investments, their market positioning differs sharply. Alector operates in neurodegeneration, an area with high unmet need but lengthy, high-risk development timelines; its setback pushed meaningful value creation further into the future. Editas operates in genetic medicine with a single, sharply defined lead program and a near-term, data-rich catalyst path through 2027.
On momentum, Editas has benefited from a concrete positive development—clinical clearance and an analyst upgrade—while Alector is still absorbing the fallout from a failed trial and a valuation reset. On financial stability, Editas' stated cash runway into 2028 compares favorably with Alector's leaner, earlier-stage repositioning. Risk factors also diverge: Alector's exposure is concentrated in unproven early-stage science and delivery technology, whereas Editas faces execution risk in a first-in-human trial in a competitive cholesterol market. Sector exposure is another contrast, with neurodegeneration and gene editing carrying different regulatory, competitive, and reimbursement dynamics.
Based on observable factors such as trend consistency, catalyst timing, financial runway, and recent sentiment, Tickeron's AI would likely lean toward EDIT in the current environment. Editas pairs a clearer near-term catalyst—clinical dosing and a 2027 data readout—with a longer cash runway and a constructive recent upgrade. Alector's early-stage repositioning carries genuine optionality but offers fewer near-term signposts for trend confirmation. This assessment is probabilistic rather than definitive: both names remain high-risk, and shifts in clinical data, financing, or broader biotech sentiment could quickly change the relative picture.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Stochastic Oscillator for ALEC moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 64 similar instances where the indicator exited the overbought zone. In 58 of the 64 cases the stock moved lower. This puts the odds of a downward move at 90%.
The 10-day RSI Indicator for ALEC moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ALEC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALEC entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ALEC as a result. In 74 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for ALEC just turned positive on October 27, 2026. Looking at past instances where ALEC's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
ALEC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ALEC crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +6.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 218 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-25.646) is normal, around the industry mean (3.498). P/E Ratio (-2.101) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
EDIT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 11, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In 46 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 75 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 125 of 154 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ALEC | EDIT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 35 | 72 | |
P/E GROWTH RATING 1..100 | 93 | 30 | |
SEASONALITY SCORE 1..100 | 29 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALEC's Valuation (6) in the Biotechnology industry is somewhat better than the same rating for EDIT (53). This means that ALEC’s stock grew somewhat faster than EDIT’s over the last 12 months.
ALEC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that ALEC’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's SMR Rating (99) in the Biotechnology industry is in the same range as ALEC (100). This means that EDIT’s stock grew similarly to ALEC’s over the last 12 months.
ALEC's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for EDIT (72). This means that ALEC’s stock grew somewhat faster than EDIT’s over the last 12 months.
EDIT's P/E Growth Rating (30) in the Biotechnology industry is somewhat better than the same rating for ALEC (93). This means that EDIT’s stock grew somewhat faster than ALEC’s over the last 12 months.
| ALEC | EDIT | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 85% | N/A |
| Stochastic ODDS (%) | 4 days ago 90% | 4 days ago 83% |
| Momentum ODDS (%) | 4 days ago 76% | 4 days ago 89% |
| MACD ODDS (%) | 4 days ago 85% | 4 days ago 90% |
| TrendWeek ODDS (%) | 4 days ago 83% | 4 days ago 90% |
| TrendMonth ODDS (%) | 4 days ago 80% | 4 days ago 89% |
| Advances ODDS (%) | 6 days ago 84% | 8 days ago 80% |
| Declines ODDS (%) | 14 days ago 87% | 5 days ago 90% |
| BollingerBands ODDS (%) | 4 days ago 84% | 4 days ago 76% |
| Aroon ODDS (%) | 4 days ago 82% | 4 days ago 81% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALEC’s FA Score shows that 1 FA rating(s) are green while EDIT’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALEC’s TA Score shows that 5 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).
ALEC (@Biotechnology) experienced а +10.92% price change this week, while EDIT (@Biotechnology) price change was -15.56% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
ALEC is expected to report earnings on Mar 02, 2027.
EDIT is expected to report earnings on Feb 25, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ALEC has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALEC jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To ALEC | 1D Price Change % | ||
|---|---|---|---|---|
| ALEC | 100% | +3.67% | ||
| EDIT - ALEC | 49% Loosely correlated | +1.40% | ||
| BCYC - ALEC | 47% Loosely correlated | -2.32% | ||
| VYGR - ALEC | 43% Loosely correlated | +1.76% | ||
| ARVN - ALEC | 43% Loosely correlated | -0.73% | ||
| PRTA - ALEC | 42% Loosely correlated | -0.85% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| UPSX | 5.77 | 0.22 | +3.96% |
| Tradr 2X Long UPST Daily ETF (UPSX) | |||
| FNDA | 36.21 | 0.04 | +0.11% |
| Schwab Fundamental U.S. Small Company ETF (FNDA) | |||
| ITWO | 42.59 | -0.14 | -0.33% |
| ProShares Russell 2000 High Income ETF (ITWO) | |||
| SEEM | 34.98 | -0.28 | -0.80% |
| SEI Select Emerging Markets Equity ETF (SEEM) | |||
| EGGS | 28.51 | -0.67 | -2.29% |
| NestYield Total Return Guard ETF (EGGS) | |||